Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 9, 2026

Aduro Clean Technologies Unveils Low-Energy Recycling Tech, Eyes First Netherlands Unit Scaling Up

View original at finance.yahoo.com
“Aduro says it is funded with about CAD 40 million and remains focused on execution.”
Verbatim excerpt from the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The company is quite aggressive in its approach

    60% confidence

  • Aduro is funded with about CAD 40 million

    60% confidence

  • Aduro's addressable market across its segments is more than $200 billion today

    60% confidence

  • Modular commercial units can be built in under a year

    60% confidence

  • The pilot system is commissioned and the team is troubleshooting, doing a lot of learning out of it

    60% confidence

  • Aduro's process produces circular naphtha—an oil-like output—from waste plastic

    60% confidence

  • Permitting and regulation are the main near-term hurdle to meeting a 2027 revenue/commissioning target

    60% confidence

  • HCT operates at lower energy, offers higher tolerance to contamination, and delivers a higher yield of materials that can return to plastic building blocks compared to pyrolysis

    60% confidence

  • Today, in 2026, we have an up and running pilot

    60% confidence

Data points we hold from this source

Aduro Clean Technologies Inc. · addressable market200 USD
Aduro Clean Technologies Inc. · cash40 million_CAD
Aduro Clean Technologies Inc. · module capacity25000 tons_per_module
Aduro Clean Technologies Inc. · target capacity100000 tons
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Aduro Clean Technologies Unveils Low-Energy Recycling Tech, Eyes First Netherlands Unit Scaling Up — Source | Via News | Finance Via News